Insulet Corp
Geschlossen
BrancheGesundheitswesen
145.05 1.14
Übersicht
Veränderung der Aktienkurses
24h
Min
141.4
Max
146.11
Einkommen | -11M 91M |
|---|---|
Verkäufe | -22M 762M |
KGV Branchendurchschnitt | 34.612 49.712 |
EPS | 1.3 |
Gewinnspanne | 11.96 |
Angestellte | 5,400 |
EBITDA | -23M 154M |
Empfehlungen | Starkes Kaufsignal |
|---|---|
12-Monats-Prognose | +59.8% upside |
Nächstes Ergebnis | 6. Aug. 2026 |
|---|
Marktkapitalisierung | -1.6B 10B |
|---|---|
Vorheriger Eröffnungskurs | 143.91 |
Vorheriger Schlusskurs | 145.05 |
Nachrichtenstimmung
By Acuity
61%
39%
269 / 342 Ranking in Healthcare
Insulet Corp Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.